22 results about "Lungs metastasis" patented technology

This invention relates to the application of β-sitosterol glycoside in the preparation of products for treating lung cancer. This invention creatively provides a new use for the active monomer β-sitosterol glycoside, demonstrating that β-sitosterol glycoside can significantly inhibit the migration ability of lung cancer cells at doses without cell proliferation inhibitors, clarifying the specificity of its anti-metastatic effect, and laying the foundation for further new drug development of this monomer component. Through an in vivo mouse lung metastasis model, this invention demonstrates that β-sitosterol glycoside effectively inhibits the formation of lung metastases while exhibiting no significant toxic side effects in experimental animals, demonstrating high safety, and providing a new candidate molecule for the development of low-toxicity, highly effective anti-lung cancer metastasis drugs.

The application provides a combined drug, a liposome, a biomimetic liposome, a preparation method of the combined drug, the liposome and the biomimetic liposome, and application of the combined drug, the liposome and the biomimetic liposome in preparation of an anti-breast cancer lung metastasis drug, and belongs to the technical field of biological medicines. The combined drug comprises panatinib and ginsenoside Rg3. The application further provides a liposome PNT-Rg3-Lipo for simultaneously loading the two, and a biomimetic liposome MM / PNT-Rg3-Lipo coated with a macrophage membrane. Experiments show that the combination of the two can synergistically regulate chemokines CXCL1 , CXCL2 and CXCL11 , and the effect is better than the sum of the single use. The MM / PNT-Rg3-Lipo has uniform particle size, retains integrin alpha 4 / beta 1 functional proteins, can target lung metastases, significantly reduces metastatic nodules, and has good biocompatibility. The application provides an effective new strategy for resisting breast cancer lung metastasis.

The present application relates to the application of long-chain non-coding RNA HILAR inhibitor in the preparation of drugs for preventing or / and treating lung adenocarcinoma metastasis. The present application provides specific intervention means for HILAR, and verifies the effectiveness of inhibiting lung adenocarcinoma metastasis: after the expression of HILAR is targeted and silenced in vitro by small interfering RNA technology, the invasion ability of lung adenocarcinoma cells is significantly inhibited, and the metastasis phenotype is obviously reversed; more importantly, through the delivery of short hairpin RNA by adeno-associated virus vector, the formation and development of lung metastasis are effectively reduced in a lung adenocarcinoma metastasis mouse model, and the in vivo imaging shows that the tumor luminescence signal intensity of the experimental group is continuously lower than that of the control group, and the overall survival condition of the animal is improved.

The application relates to application of an SREBP2 inhibitor in preparation of a drug for treating SREBP2-CCDC25 axis-mediated triple-negative breast cancer metastasis, and discloses a mechanism of SREBP2 in regulating CCDC25 transcription and translation levels through molecular biology, cell biology and animal experiment research, further discloses that SCAP inhibitors (lycorine, adipose inhibitor) inhibit TNBC lung metastasis by regulating the SREBP2-CCDC25 axis, and provides data support for further application of the SCAP inhibitor in treating TNBC (MDA-MB-231 cancer cells, BT-549 cancer cells) lung metastasis.

This invention belongs to the field of biomedical technology and discloses the application of olaparib in combination with taquimod in the preparation of anti-tumor metastasis drugs. This invention is the first to discover that olaparib and taquimod, even at low concentrations (i.e., concentrations that do not affect tumor cell proliferation), can effectively inhibit the invasion and metastasis of breast cancer cells, exhibiting high safety. Furthermore, when olaparib and taquimod are used in combination, the inhibitory effect on breast cell invasion and metastasis shows a synergistic enhancement trend, with significantly better efficacy than single-drug therapy, overcoming the limitations of monotherapy. Moreover, the combination of olaparib and taquimod can effectively inhibit lung metastasis of breast cancer, providing a new theoretical basis and medication regimen for anti-metastasis treatment of breast cancer.

The application discloses a culture medium for constructing a liver cancer lung metastasis microtumor model and application thereof. The application relates to the technical field of biology, and provides a culture medium for constructing a liver cancer lung metastasis microtumor model, which is composed of three antibacterial and antifungal agents, HEPES, GlutaMax, human recombinant proteins EGF, HGF, IL-2, IL-15, R-spondin1, CXCL12, recombinant human lung surfactant proteins SP-A, SP-D, forskolin, A83-01, N-acetyl-L-cysteine, nicotinamide, N2 additives, B27 and a basic culture medium. The culture success rate of the liver cancer lung metastasis microtumor model is effectively improved.

The application provides application of idebenone in preparation of a medicine for treating osteosarcoma. The application of idebenone or a pharmaceutically acceptable salt thereof in preparation of the medicine for treating osteosarcoma is achieved by carrying out proliferation experiments (CCK8 method) and invasion experiments (transwell invasion experiment) of osteosarcoma cell lines in vitro, quantitative analysis of cell viability in the CCK8 method proliferation experiment and quantitative analysis of the number of penetrated cells in the transwell invasion experiment; and constructing a nude mouse CDX (cell-derived xenograft) model, a PDX (human-derived xenograft) model and a tibial orthotopic / metastatic tumor model, intraperitoneally injecting idebenone, and quantitatively analyzing the tumor volume and tumor weight in the CDX model, the tumor volume and tumor weight in the PDX model and the tumor volume, the weight of the affected limb and the number of lung metastases in the tibial orthotopic / metastatic tumor model, which fully indicates that idebenone can inhibit the proliferation, invasion and metastasis of osteosarcoma.

The application discloses a flaxseed oil body carrier for treating hepatocellular carcinoma by inducing immunogenic cell death and a preparation method and application thereof. The flaxseed oil body is obtained by a water extraction method, then curcumin is loaded on the flaxseed oil body, and then mineralization is performed to obtain the flaxseed oil body carrier for treating hepatocellular carcinoma by inducing immunogenic cell death. Through in vitro and in vivo experiments, it is proved that the carrier can effectively inhibit the growth of hepatocellular carcinoma, and the characterization results show that the carrier can further enhance the tumor killing effect by activating the immune system. Further, after the anti-PD-L1 is combined with the carrier, a synergistic effect can be produced, the treatment effect of the alpha PD-L1 immunotherapy on the anti-HCC lung metastasis is enhanced, and it is proved that the carrier can be used for combining the alpha PD-L1 immunotherapy to enhance the anti-tumor effect, and has a wide application prospect.

This invention belongs to the field of biomedical technology, specifically relating to the application of erythrocyte-derived exosomes in the preparation of drugs for melanoma lung metastasis. This invention discovers that treatment with erythrocyte-derived exosomes can inhibit the metastatic ability of malignant melanoma, thus proposing the application of erythrocyte-derived exosomes in the preparation of drugs for melanoma lung metastasis.

This invention provides a nucleic acid aptamer that targets and binds to the IGF2BP2 protein and its application, belonging to the field of pharmaceutical technology. This invention is the first to design a highly specific nucleic acid aptamer targeting the RNA recognition protein IGF2BP2, obtaining a nucleic acid aptamer that can target and specifically bind to the IGF2BP2 protein (see SEQ ID No. 1-2). This nucleic acid aptamer can effectively inhibit the activity of tumor cells, tumor stem cells, and breast cancer brain metastases, breast cancer lung metastases, breast cancer liver metastases, breast cancer kidney metastases, and breast cancer bone metastases, providing a new drug component for the treatment of malignant and refractory tumors (especially glioblastoma and distant metastatic breast cancer). Furthermore, it was discovered that modification with N6-methyldeoxyadenosine monophosphate can further enhance the specificity of the nucleic acid aptamer and strengthen its efficacy in inhibiting tumor cell activity.

The application provides a slightly acid response type biomimetic nanovesicle and a preparation method and application thereof. The outer layer of the slightly acid response type biomimetic nanovesicle is composed of a PD-1 biological cell membrane, and apatinib is loaded into the slightly acid response type PEG-PAEs nanoparticle hydrophobic inner core. Apa-PPNP@mPD-1, as a new dosage form of combined administration of a small molecule inhibitor and a large molecule inhibitor, can precisely co-deliver apatinib and PD-1 protein to tumor tissues, release the drug in response to the slightly acid environment of the tumor, has a significant treatment effect of tumor growth regression and effective inhibition of lung metastasis, and also avoids toxic side effects on normal tissues, and has good biocompatibility.

This invention discloses the application of the CYYR1 gene in the preparation of drugs for treating YAP-highly activated tumors, belonging to the field of biotechnology. This invention provides the application of the CYYR1 gene in the preparation of drugs for treating YAP-highly activated tumors, wherein the drugs are capable of promoting CYYR1 gene overexpression. Experiments have shown that overexpression of CYYR1 can significantly inhibit the proliferation, invasion, and colony formation of YAP-highly activated breast cancer cells MDA-MB-231, and inhibit tumorigenesis and lung metastasis in nude mice. Therefore, the CYYR1 gene can be used as a drug, drug target, or target gene in gene therapy for the treatment of YAP-highly activated tumors. This invention provides new diagnostic and therapeutic ideas and methods for the treatment of YAP-highly activated tumors.

This invention belongs to the field of biomedical technology and discloses the application of exosomal lncOSLMT in the diagnosis and treatment of osteosarcoma lung metastases. This invention discloses the application of reagents for detecting lncOSLMT in the preparation of products for risk diagnosis or prognostic assessment of osteosarcoma lung metastases. Through research, this invention found that lncOSLMT selectively accumulates in exosomes released by osteosarcoma cells with high metastatic potential. Its elevated expression is positively correlated with the incidence of lung metastasis and serves as an independent prognostic factor for poor prognosis in osteosarcoma patients. This invention elucidates the regulatory role of lncOSLMT in the pre-metastatic microenvironment of osteosarcoma lung metastases and its effect on lung metastasis, clarifying that targeting lncOSLMT has significant clinical translational value for targeted treatment of osteosarcoma lung metastases, especially in osteosarcoma liquid biopsy and early metastasis prediction, and is of great importance in ensuring adequate clinical safety.

This application discloses an antisense oligonucleotide targeting the long non-coding RNA Lnc01876 and its applications. The antisense oligonucleotide has the sequence shown in SEQ ID NO:2 or SEQ ID NO:3 and efficiently knocks down Lnc01876 expression at a concentration of 50 nM. This antisense oligonucleotide can be used to prepare anti-CRC metastasis drugs, significantly inhibiting CRC cell proliferation, migration, and invasion, and suppressing tumor growth and lung metastasis in vivo.

The application belongs to the technical field of biological medicine, and particularly relates to PRMT2 interfering lentivirus and application thereof. The application designs the interfering lentivirus by taking PRMT2 as a target, and studies the role and mechanism of the interfering lentivirus in triple-negative breast cancer. Experiments show that the interfering lentivirus PRMT2-KD1 and PRMT2-KD2 can down-regulate PRMT2 gene expression, inhibit cell migration, invasion and aerobic glycolysis; the PRMT2 high-expression plasmid combined with a glycolysis inhibitor verifies that PRMT2 affects cell migration and invasion by regulating aerobic glycolysis; animal experiments show that the PRMT2 interfering lentivirus can inhibit lung metastasis of mouse triple-negative breast cancer. The above results suggest that PRMT2 can be used as a drug target for the treatment of triple-negative breast cancer metastasis.

This specification provides lipid-conjugate polyethyleneimine (PEI) compounds of formula (I) that are useful for forming delivery systems such as lipid nanoparticles for delivering active substances (e.g., nucleic acid molecules) to cells (e.g., endothelial cells). This specification also provides methods for treating atherosclerosis, cardiovascular disease, pulmonary hypertension (e.g., pulmonary arterial hypertension or secondary pulmonary hypertension), lung cancer, lung metastases, chronic obstructive pulmonary disease (COPD), bronchiolitis obliterans, bronchiolitis obliterans with organizing pneumonia (BOOP), pulmonary fibrosis, or fibrous lung disease, comprising administering a pharmaceutical composition comprising a lipid-conjugate polyethyleneimine (PEI) compound of formula (I), an active substance, and a pharmaceutically acceptable excipient to a target.

This invention provides an injectable pH-responsive hydrogel nanoparticle, its preparation method, and its applications, relating to the field of bionanomedicine technology. First, nintedanib, zinc ions, and D780 are self-assembled to prepare nanoparticles (NPs). Then, the nanoparticles are cross-linked with an OP hydrogel to obtain injectable pH-responsive hydrogel nanoparticles (OP@NPs). These OP@NPs not only possess a stable structure and injectability but also achieve efficient drug delivery through a pH-triggered release mechanism. Furthermore, OP@NPs can significantly enhance anti-tumor immune responses and effectively inhibit tumor growth by activating in vivo immune cells, improving lactate metabolism, and enhancing immune cell function. They exhibit potent anti-tumor effects and inhibition of osteosarcoma lung metastasis both in vivo and in vitro. When used in combination with the PD-1 antagonist pembrolizumab, they demonstrate great potential as a sensitizer for anti-tumor immunotherapy. This invention provides innovative strategies and new insights for osteosarcoma immunotherapy.

This invention relates to a NIR-II charge transfer complex (CTCs) and its preparation and application. Using TFTQ as the core acceptor (A) moiety, this invention co-assembles a series of CTCs with various donor moiety moieties. Through systematic screening, DBTTF (D2) was identified as the optimal electron donor. By analyzing the structure-activity relationship between stoichiometry and material properties, this invention discovers that 2A-D2, with a acceptor-to-donor molar ratio of 2:1, possesses both a high molar extinction coefficient and loose molecular packing. This structure not only promotes nonradiative transitions, achieving a photothermal conversion efficiency of 40.3%, but also alleviates aggregation-induced quenching effects through loose molecular arrangement, increasing reactive oxygen species (ROS) production and resolving the fundamental contradiction between NIR-II photothermal conversion and ROS generation. 2A-D2-mediated photodynamic-photothermal combined therapy exhibits potent anti-tumor effects. Irradiation with a 1064 nm laser induces mitochondrial dysfunction and DNA damage in tumor cells, achieving a tumor inhibition rate of up to 94.5%, and significantly inhibiting lung metastasis, providing a new approach for precise ablation therapy of deep tumors.

The application relates to the field of biological medicine, in particular to a human renal clear cell carcinoma high-metastasis cell line, which is classified and named as human renal clear cell carcinoma high-metastasis cell 786O-M2-Luc Homo sapiens, and the preservation number is CCTCC No: C2025339. The renal clear cell carcinoma high-metastasis cell line can be applied to constructing a renal clear cell carcinoma high-metastasis cell model or an animal model. The cell line of the application can form a stable orthotopic tumor in an immunodeficient mouse, can cause distant organ metastasis such as lung metastasis, can express a GFP and Luciferase double-reporting system, and is convenient for in-vitro sorting and in-vivo IVIS imaging tracking. The cell line of the application retains the typical renal cell carcinoma characteristics of 786-O cells in vitro, but has stronger proliferation, migration and invasion capacity, and can be used as a tool model for renal cancer metastasis mechanism research and drug screening.